Paper Details

  1. Home
  2. Paper Details

Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2.

Author: GrüllichCarsten

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Cabozantinib is a tyrosine kinase inhibitor that targets multiple pathways involved in cancer growth. It is approved for treating medullary thyroid cancer and renal cell cancer. Cabozantinib demonstrated effectiveness in patients with renal cell cancer progressing after first-line treatment, especially those with bone metastasis. While side effects like diarrhea, hypertension, fatigue, and hand-foot syndrome can occur, the benefits of cabozantinib for these patients are significant.
Paper Details　
Original Abstract of the Article :
Cabozantinib is a receptor tyrosine kinase inhibitor (TKI) with activity against a broad range of targets, including MET, RET, AXL, VEGFR2, FLT3, and c-KIT. Activity of cabozantinib towards a broad range of tumor models could be detected in several preclinical studies. Of note, cabozantinib decrease...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/978-3-319-91442-8_5

データ提供：米国国立医学図書館（NLM）

Cabozantinib: A Versatile Multi-kinase Inhibitor

Cabozantinib is a promising new drug that has demonstrated its ability to target multiple kinases, including MET, RET, AXL, and VEGFR2. This research delves into the clinical applications of cabozantinib in treating medullary thyroid cancer (MTC) and renal cell cancer (RCC). The authors highlight the drug's effectiveness in treating MTC, where RET mutations play a crucial role in tumorigenesis. They also discuss the potential of cabozantinib in addressing resistance to VEGFR-targeted therapies in RCC. This research underscores the versatility of cabozantinib and its potential to address various cancers.

A Multi-faceted Approach to Cancer Treatment

Cabozantinib is like a skilled desert nomad, able to navigate a variety of landscapes and challenges. Its ability to target multiple kinases makes it a versatile tool in the fight against cancer. This research is like a map, guiding us through the complex terrain of cancer treatment and highlighting the potential of multi-kinase inhibitors to address different types of cancer.

Hope for a Broader Range of Patients

The development of multi-kinase inhibitors like cabozantinib offers hope for a broader range of cancer patients. It's like discovering a new oasis in the desert, providing a source of relief and renewal for those struggling with different types of cancer. This research underscores the importance of continuing to explore innovative drug development strategies that can target multiple pathways and provide effective treatment options for a wider range of cancers.

Dr.Camel's Conclusion

This research on cabozantinib is a testament to the progress in cancer treatment and the pursuit of innovative therapies. It's like a camel caravan, carrying the promise of healing across the vast and challenging desert of cancer. Cabozantinib's versatility and effectiveness in treating different types of cancer offer a glimmer of hope for a healthier future.

Date :
  1. Date Completed 2018-11-13
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

30069760

DOI: Digital Object Identifier

10.1007/978-3-319-91442-8_5

Related Literature

Article Analysis
・Side Effects of cabozantinib (thyroid cancer)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.